Filter Results :

Your search for Therapeutic Class Report returned 5 reports

Sort by


Therapeutic Class Report Overview - Rituxan Biosimilar

04 Feb 2013  |  Published by:  MP Advisors
The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituxim...

$ 2,000.00

Read More

Therapeutic Class Report Overview : Hepatitis C Virus Infection

04 Feb 2013  |  Published by:  MP Advisors
The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treatin...

$ 1,000.00

Read More

Therapeutic Class Report Overview - Future Of GPR Agonist

04 Feb 2013  |  Published by:  MP Advisors
Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening of glycemic control and ~half of them end up with daily insulin. Increasing epidemiology of Type 2 diabet...

$ 1,000.00

Read More

Therapeutic Class Report Overview - Hemophilia

04 Feb 2013  |  Published by:  MP Advisors
Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors – Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX protei...

$ 2,000.00

Read More

Therapeutic Class Report Overview - Japan Biosimilars

28 Jan 2013  |  Published by:  MP Advisors
¥200b worth of biologic products is going off patent by 2015 and this value exceeds ~ ¥500b if we include products that will see their patent expiries by 2021 in Japan. There are a number of reasons to believe that follow-on-biologics or biosimilars will not replicate the lethargic growth story o...

$ 1,000.00

Read More
Total 5 records.